Oric Pharmaceuticals
ORIC
112 hedge funds and large institutions have $879M invested in Oric Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.
2,679% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $117K
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
87% more capital invested
Capital invested by funds: $470M → $879M (+$409M)
22% more funds holding
Funds holding: 92 → 112 (+20)
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
1.21% more ownership
Funds ownership: 93.71% → 94.92% (+1.2%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$47.5M |
| 2 |
CC
Commodore Capital
New York
|
+$23.8M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$23.8M |
| 4 |
VA
VR Adviser
New York
|
+$23.4M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.5M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$14.5M |
| 3 |
Morgan Stanley
New York
|
-$7.84M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$6.07M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.79M |
ORIC Hedge Fund Activity: Q1 2024 in Review
112 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2024, worth a combined $879M — up 87% from $470M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ORIC positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $47.5M. The largest seller was Fidelity Investments, cutting an estimated $23.5M.
- 112 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2024, up from 92 in Q4 2023.
- Funds reported $879M of Oric Pharmaceuticals stock for Q1 2024, up 87% quarter-over-quarter.
- 35 funds opened new Oric Pharmaceuticals positions in Q1 2024 and 15 closed out, a net change of +20 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2024 was Viking Global Investors, an estimated $47.5M added.
- The largest Oric Pharmaceuticals seller in Q1 2024 was Fidelity Investments, an estimated $23.5M sold.
Based on aggregated 13F filings for Q1 2024.